Clinical Education Center
- No FAQs found
- ABL Kinase Domain Mutation in CML, Cell-based
- ABO Group and Rh Type
- Acid-Fast Bacillus (AFB) Identification, Sequencing and Stain, Paraffin Block
- ADAMTS13 Activity with Reflex to ADAMTS13 Inhibitor
- Alcohol Metabolites, Quantitative, Urine
- Alpha-Globin Common Mutation Analysis
- Alpha-Globin Gene Deletion or Duplication
- Alpha-Globin Gene Sequencing
- Anti-Müllerian Hormone AssessR™
- Anti-PF4 and Serotonin Release Assay (SRA) for Diagnosing Heparin-induced Thrombocytopenia/Thrombosis (HIT/HITT)
- Antiphospholipid Antibodies
- ASCVD Risk Panel with Score
- Autoimmune Epilepsy Evaluation
- Autoimmune Diseases, Tests for
- B-cell and T-cell Clonality Assays by PCR
- B-Type Natriuretic Peptide (BNP)
- BCR-ABL1 Gene Rearrangement, Quantitative PCR
- Beta-Globin Complete
- BRCAvantage®, Ashkenazi Jewish Screen
- BRCAvantage®, Rearrangements
- BRCAvantage™, Comprehensive
- BRCAvantage™, Single Site
- CDH1 Sequencing and Deletion/Duplication
- Clostridium difficile Diagnostic Testing
- C1 Inhibitor, Protein and Functional Tests
- Calreticulin (CALR) Mutation Analysis
- Carbapenem Resistant Enterobacteriaceae Culture Screen
- Cardio IQ Lipoprotein Fractionation, Ion Mobility
- Cervical Cancer, TERC, FISH
- CFvantage® Cystic Fibrosis Expanded Screen
- Chlamydia trachomatis, TMA
- Chlamydia trachomatis/Neisseria gonorrhoeae RNA, TMA
- Chromosomal Microarray, POC, ClariSure®, Oligo-SNP
- Chromosomal Microarray, Postnatal, ClariSure® Oligo-SNP
- Chromosome Analysis and AFP with Reflex to AChE, Fetal Hgb, Amniotic Fluid
- Chromosome Analysis, Amniotic Fluid
- Chromosome Analysis, Blood
- Chromosome Analysis, Blood with Reflex to Postnatal, ClariSure® Oligo-SNP Array
- Chromosome Analysis, Chorionic Villus Sample
- Chromosome Analysis, High Resolution
- Chromosome Analysis, High Resolution with Reflex to Postnatal, ClariSure® Oligo-SNP Array
- Chromosome Analysis, Mosaicism
- Chromosome Analysis, Neonatal Blood
- Chromosome Analysis, Sister Chromatid Exchange
- Chromosome Analysis, Tissue
- Chromosome DEB Assay for Fanconi anemia
- Chronic Lymphocytic Leukemia (CLL) - Diagnostic and Prognostic Testing
- Culture, Fungus
- Culture, Urine, Routine
- Cystic Fibrosis Screen
- Cytomegalovirus (CMV) and Epstein Barr Virus (EBV) PCR
- D-Dimer, Quantitative
- Dementia, Secondary Causes
- Dengue Virus Testing
- Diabetes Risk Panel with Score and Cardio IQ® Diabetes Risk Panel with Score
- Drug Testing, General Toxicology (Blood, Urine, or Serum)
- Drug Toxicology Alcohol Metab, QN, Oral Fluid
- Drug Toxicology Monitoring, Oral Fluid Testing
- Factor V (Leiden) Mutation Analysis
- Familial Mediterranean Fever Mutation Analysis
- First Trimester Screen, hCG
- First Trimester Screen, Hyperglycosylated hCG (h-hCG)
- FISH, Angelman
- FISH, MET Amplification
- FISH, Myeloma, 17p-, rea 14q32 with Reflexes
- FISH, Prader-Willi
- FISH, Prenatal Screen
- No FAQs found
- HCV Genotyping
- Helicobacter pylori (H pylori) Antibody Discontinuation
- Heparin, Anti-Xa
- Hepatitis B Surface Antibody, Quantitative
- Hepatitis C Antibody with Reflex to HCV RNA, PCR with Reflex to Genotype
- Hepatitis C Viral RNA Genotype 1 NS5A Drug-resistance
- Hepatitis C Viral RNA Genotype 3 NS5A Drug Resistance
- Hepatitis C Viral RNA NS3 Drug Resistance
- Hepatitis C, RNA, Quantitative, PCR
- Hereditary Cancer Panels: MYvantageTM Hereditary Comprehensive Cancer Panel and GIvantageTM Hereditary Colorectal Cancer Panel
- Hereditary Hemochromatosis DNA Mutation Analysis
- Herpes Simplex Virus (HSV) Type-Specific IgG Antibodies
- Herpes Simplex Virus Type 2 (HSV-2) IgG Inhibition, ELISA
- HIV-1 Coreceptor Tropism, Proviral DNA
- HIV-1 Coreceptor Tropism, Ultradeep Sequencing
- HIV-1 Integrase Genotype
- HIV-1/2 Antigen and Antibodies, Fourth Generation, with Reflexes
- HPV mRNA E6/E7
- Influenza A and B Antigen, Immunoassay
- Influenza Type A and B Antibodies
- Insulin, Intact, LC/MS/MS
- Integrated Screen, Part 1
- Integrated Screen, Part 2
- Intrinsic Factor Blocking Antibody
- No FAQs found
- No FAQs found
- Maternal Serum AFP
- Melanoma, BRAF V600E and V600K Mutation Analysis, THxID®
- Metanephrines, Fractionated, Free, LC/MS/MS, Plasma
- Methylenetetrahydrofolate Reductase (MTHFR), DNA Analysis
- Microalbumin (Urinary Albumin Excretion)
- Pain Management and CYP2D6/CYP2C19
- Pain Management, Naltrexone, Quantitative, Urine
- Partial Thromboplastin Time, Activated (aPTT)
- Penta Screen
- PIK3CA Mutation Analysis
- PNH with FLAER (High Sensitivity)
- Prothrombin Time with INR
- PTH, Intact and Calcium
- Streptococcus pneumoniae (Pneumococcal) Antibody Tests
- Saccharomyces cerevisiae Antibodies (ASCA) (IgG, IgA)
- Sequential Integrated Screen, Part 1
- Sequential Integrated Screen, Part 2
- Serum Integrated Screen, Part 1
- Serum Integrated Screen, Part 2
- Serum Pregnancy Tests
- Sickle Cell Screen
- Stepwise, Part 1
- Stepwise, Part 2
- SureSwab® Trichomonas vaginalis RNA, Qualitative TMA
- SureSwab®, Candidiasis, PCR
- TP53 Sequencing and Deletion/Duplication
- T4, Free
- Tamoxifen and Metabolites, LC-MS/MS
- Testosterone Testing
- Total Testosterone, LC/MS/MS
- Triple Screen
- No FAQs found
- No FAQs found
- No FAQs found
Cardio IQ Lipoprotein Fractionation, Ion MobilityTest code(s) 91604
Question 1. What is ion mobility lipoprotein fractionation?
Ion mobility lipoprotein fractionation is a technology that uses gas-phase (laminar flow) electrophoresis to separate unmodified lipoproteins on the basis of size. Following the separation, each lipoprotein particle is directly detected and counted as it exits the separation chamber.
Ion mobility fractionation is the latest technology in the evolution of advanced lipid subclass measurement. It has evolved from the analytical ultracentrifugation (AnUC) and segmented gradient gel electrophoresis (SGGE) technologies developed at the University of California, Berkeley. Ion mobility incorporates and improves on the best features of advanced lipoprotein measurement methods. It combines high resolution separation of the full spectrum of lipoprotein particles along with direct quantitation of particles in each lipoprotein subclass. The high resolution of ion mobility’s lipoprotein subfractionation is comparable to that seen with AnUC and SGGE methods. Thus, the extensive literature supporting the clinical use of lipoprotein subclasses derived from these 2 methods can be applied to ion mobility-derived subclasses as well.
The size of the lipoprotein particles detected and counted are not affected by particle modifications. The particles are unaltered by stains or ultracentrifugation forces. Ionized lipoprotein particles are electrophoretically separated in a gas phase, and lipoprotein particles are distinguished on the basis of size. Size-separated particles are detected and counted by light scattering.
Ionized lipoproteins migrate across a laminar gas-phase flow, based on size and electrical field. Only a single size of lipoprotein will exit the field and be isolated (green line) at any point across the voltage gradient; larger and smaller lipoproteins (dotted black) are not collected. As the voltage ramps across the gradient, all of the lipoproteins are captured.
Question 2. Which lipoprotein fractions are reported and why?
Ion mobility technology precisely quantifies lipoprotein fractions across the entire lipoprotein spectrum; this comprises VLDL, IDL, LDL, and HDL particles.1 However, to facilitate risk assessment, Quest Diagnostics reports only those measurements that were significantly correlated with CVD events in a cohort of men and women from the prospective Malmo Diet and Cancer Study2:
- Small, medium, and total LDL particle numbers (P ≤0.004)
- LDL peak size (P = 0.009) and the associated LDL pattern
- Large HDL particle number (P <0.001)
The focus on these measurements is consistent with identification of the “atherogenic lipoprotein phenotype” first proposed 2 decades ago.3,4
An elevated total LDL particle number is associated with a 1.4-fold increase in CVD risk.5 Similarly, elevated small and medium LDL particle numbers have been associated with a 1.3- to 1.4-fold increase.5
Ion mobility identifies 2 main subclasses of HDL: large HDL and small HDL. Large HDL may help protect the arterial wall due to its antioxidant properties. A decreased large HDL subclass suggests increased CVD risk.
Question 3. How do ion mobility- and NMR-derived LDL particles compare?
The NMR-derived LDL particle number (LDL-P, nmol/L) includes the 3 LDL subclasses and IDL. The concentration is measured indirectly from NMR signals emanating from terminal methyl groups in the lipoprotein particle shell and core.6
In contrast, the ion mobility-derived total LDL particle concentrations (nmol/L), ie, LDL small and medium subclasses, are a direct detection and quantitation of the total number of LDL particles.1
Question 4. How does the ion mobility-derived total LDL particle measurement compare to an apolipoprotein B measurement?
The ion mobility-derived total LDL particle concentration (nmol/L) is a direct detection and quantitation of the total number of LDL particles.1
Apolipoprotein B (apo B) measurements represent the number of LDL particles and the overall number of atherogenic particles. Commercially available apo B assays measure lipoproteins containing apo B-100 and apo B-48. This includes the apo B component of LDL, IDL, VLDL, lipoprotein(a), and chylomicrons. Results are reported as mg/dL.
Question 5. How should discrepant apolipoprotein B and ion mobility-derived total LDL particles be interpreted?
When assessing a person’s risk for CVD, and especially when assessing residual risk, both markers may be considered even when they place the person in different risk categories. This is because the apo B test measures total apo B (apo B attached to VLDL, IDL, and LDL), while the ion mobility-derived LDL particle number is specific to LDL particles.
In the same way that an elevated apo B can be considered more revealing than LDL cholesterol when characterizing residual risk, the ion mobility-derived total LDL particle number correlates better with risk associated with LDL particle number. The apo B may correlate better with the risk attributed to all apo B-containing particles (LDL, IDL, and VLDL).
Question 6. How should discrepant LDL phenotype, LDL particle size, total LDL particle number, and LDL subclass results be interpreted?
When assessing a person’s risk for CVD, all results from risk markers should be considered even when they place the person in different risk categories. This is especially important when assessing residual risk.
That being said, it is reasonable that the finer the measuring tool and the more specific the data being generated, the more insightful are the conclusions that can be made. Historically LDL subclass patterns (ie, phenotype) have been characterized as predominantly small and dense (LDL pattern B) or predominantly large and buoyant (LDL pattern A) in order to characterize populations for analysis in research studies. However, some patients classified as LDL pattern A can have an unhealthy amount of small LDL.
The LDL particle size is the mean LDL particle diameter; it reflects the average size and is a good general measure. However, it does not always accurately reflect particle distribution.
A high total LDL particle number may be the result of a high number of large LDL particles or a high number of small LDL particles. The former is not associated with increased CVD risk, but the latter would indicate a higher risk. Thus, knowledge of the individual LDL subclass contribution to the total LDL particle number helps the clinician interpret the total LDL particle number result.
Question 7. How are the optimal (O), moderate (M), and high (H) risk categories shown on the Cardio IQ™ report determined?
The cut-points are based on analysis of data from the Malmo Diet and Cancer Study cardiovascular cohort. The cohort included 4,594 individuals who were followed for 12 years. Data showed that significantly higher risk was associated with values in the upper (or lower) tertile of population values. For example, a small LDL particle number in the upper third was associated with a significantly increased risk. Thus, the O, M, and H risk categories shown on the report are based on the tertile distribution of values in this cohort.2
Question 8. How are ion mobility-derived results incorporated into an overall risk assessment?
When assessing a person’s risk for CVD, all results from risk markers should be considered even when they place the person in different risk categories. This is especially important when assessing residual risk. Below is an example that demonstrates the importance of considering multiple ion mobility-derived risk markers.
Pattern A is classified as optimal, and pattern B is classified as high risk. This is based on large population studies showing that people without coronary heart disease tend to have an abundance of large, buoyant LDL particles (pattern A), and people with coronary heart disease tend to have an abundance of smaller, dense LDL particles (pattern B).7
However, the literature suggests that CVD risk is conferred by a trio of factors that define the atherogenic lipoprotein profile (ALP).8 The ALP includes elevated small LDL particles (pattern B), low levels of high density lipoprotein (HDL) cholesterol, and often, but not always, an elevated fasting triglyceride concentration. So the LDL pattern phenotype is only one aspect of the ALP. Additionally, neither the LDL pattern phenotype nor the ALP reflect risk associated with HDL subclasses or the number of small LDL particles.
Here is an example on how LDL particle number can contribute to the overall CVD risk. Consider a patient with an optimal pattern A LDL phenotype and a high total LDL mass. If the number of small LDL particles is also high, the patient may be at increased risk despite the favorable pattern A result. Thus, quantitating lipoprotein subclasses (eg, small, medium, large) can provide important information when assessing overall CVD risk. Interpreting the favorable pattern A result as indicative of low CVD risk could mistakenly rule out treatment in a patient who could benefit from it.
Question 9. Why do you use ångström units in the Cardio IQ report?
The ångström (Å) (0.1 nm) is a unit of measure denoting the diameter (size) of a particle. This diameter is used to determine the pattern A vs pattern B LDL phenotype.
The Cardio IQ report shows the particle diameter on the horizontal axis of the lipoprotein fractionation graphical display. The ångström measurement at the apex of the major LDL lipoprotein peak is reported in both the summary results table and the ion mobility detail table, labeled as LDL Peak Size.
Question 10. How much risk is associated with various lipoprotein subclasses?
The following CVD risk associations were observed in the Malmo Diet and Cancer Study cardiovascular cohort2:
- High number of small LDL particles: 1.3 times increased risk
- High number of medium LDL particles: 1.4 times increased risk
- Low number of large HDL particles: 1.8 times increased risk
Question 11. What do the various HDL results mean?
Protection from CVD is associated with:
- High HDL-C concentration
- High number of large HDL particles
- Large, buoyant HDL phenotype
Conversely, values in the lower tertile are associated with increased risk for CVD.2
Question 12. Which therapeutic agents have an impact on lipoprotein subclasses?
Statins tend to reduce the entire LDL spectrum, large and small alike.
- Caulfield MP, Li S, Lee G, et al. Direct determination of lipoprotein particle sizes and concentrations by ion mobility analysis. Clin Chem. 2008;54:1307-1316.
- Musunuru K, Orho-Melander M, Caulfield M, et al. Ion mobility analysis of lipoprotein subfractions identifies three independent axes of cardiovascular risk. Arterioscler Thromb Vasc Biol. 2009;29:1975-1980.
- Austin MA, King MC, Vranizan KM, Krauss RM. Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation. 1990;82:495-506.
- Superko HR. Advanced lipoprotein testing and subfractionation are clinically useful. Circulation 2009;119:2383-2395.
- Musunuru K, Orho-Melander M, Caulfield MP, et al. Ion mobility analysis of lipoprotein subfractions identifies three independent axes of cardiovascular risk. Arterioscler Thromb Vasc Biol. 2009;29:1975-1980.
- Mudd JO, Borlaug BA, Johnston PV, et al. Beyond low-density lipoprotein cholesterol: defining the role of low-density lipoprotein heterogeneity in coronary artery disease. J Am Coll Cardiol. 2007;50:1735-1741.
- Superko HR. Advanced lipoprotein testing and subfractionation are clinically useful. Circulation 2009;119;2383-2395.
- Krauss RM. Lipoprotein subfractions and cardiovascular disease risk. Curr Opin Lipidol. 2010;21:305–311.
- Superko HR, Garrett BC, King SB 3rd, et al. Effect of combination nicotinic acid and gemfibrozil treatment on intermediate density lipoprotein, and subclasses of low density lipoprotein and high density lipoprotein in patients with combined hyperlipidemia. Am J Cardiol. 2009;103:387-392.
- Superko HR, Berneis KK, Williams PT, et al. Gemfibrozil reduces small low-density lipoprotein more in normolipemic subjects classified as low-density lipoprotein pattern B compared with pattern A. Am J Cardiol. 2005;96:1266-1272.